{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Luke JJ"],"funding":["n/a","NCI NIH HHS"],"pagination":["2435-2444"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11225568"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["29(13)"],"pubmed_abstract":["<h4>Purpose</h4>SYNB1891 is a live, modified strain of the probiotic Escherichia coli Nissle 1917 (EcN) engineered to produce cyclic dinucleotides under hypoxia, leading to STimulator of INterferon Genes (STING) activation in phagocytic antigen-presenting cells in tumors and activating complementary innate immune pathways.<h4>Patients and methods</h4>This first-in-human study (NCT04167137) enrolled participants with refractory advanced cancers to receive repeat intratumoral injections of SYNB1891 either alone or in combination with atezolizumab, with the primary objective of evaluating the safety and tolerability of both regimens.<h4>Results</h4>Twenty-four participants received monotherapy across six cohorts, and 8 participants received combination therapy in two cohorts. Five cytokine re"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies."],"pmcid":["PMC11225568"],"funding_grant_id":["P30 CA047904","P30 CA016672"],"pubmed_authors":["Varterasian M","Brennan AM","Sokolovska A","Riese RJ","Strauss J","Janku F","Hava DL","Medina T","Verschraegen CF","Luke JJ","Piha-Paul SA"],"additional_accession":[]},"is_claimable":false,"name":"Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies.","description":"<h4>Purpose</h4>SYNB1891 is a live, modified strain of the probiotic Escherichia coli Nissle 1917 (EcN) engineered to produce cyclic dinucleotides under hypoxia, leading to STimulator of INterferon Genes (STING) activation in phagocytic antigen-presenting cells in tumors and activating complementary innate immune pathways.<h4>Patients and methods</h4>This first-in-human study (NCT04167137) enrolled participants with refractory advanced cancers to receive repeat intratumoral injections of SYNB1891 either alone or in combination with atezolizumab, with the primary objective of evaluating the safety and tolerability of both regimens.<h4>Results</h4>Twenty-four participants received monotherapy across six cohorts, and 8 participants received combination therapy in two cohorts. Five cytokine re","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jul","modification":"2026-06-02T21:18:13.441Z","creation":"2025-04-04T12:21:16.712Z"},"accession":"S-EPMC11225568","cross_references":{"pubmed":["37227176"],"doi":["10.1158/1078-0432.CCR-23-0118","10.1158/1078-0432.ccr-23-0118"]}}